| English Name | Research Code | Highest Development Stage | Company | Indication | Clinical Trial |
|---|---|---|---|---|---|
| Dupilumab biosimilar (Jingxing Pharmaceutical) | GS101; GS-101; GS-101 (Jingxing Pharmaceutical) | Phase 3 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Qilu Pharma) | QL2108; QL-2108 | Phase 3 Clinical | Qilu Pharmaceutical Co Ltd | Asthma; Dermatitis, Atopic; Prurigo | Details |
| Tilrekimig | PF-07275315 | Phase 3 Clinical | Pfizer Inc | Asthma; Dermatitis, Atopic; Pulmonary Disease, Chronic Obstructive | Details |
| Lunsekimig | SAR-443765 | Phase 3 Clinical | Sanofi | Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis, Atopic; Inflammation; Pulmonary Disease, Chronic Obstructive | Details |
| Cendakimab | RPC-4046; ABT-308; CC-93538 | Phase 3 Clinical | Abbott Laboratories | Asthma; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG) | Details |
| Eblasakimab | MK-6105; ASLAN-004; CSL-334 | Phase 2 Clinical | Csl Ltd, Merck Sharp & Dohme Corp | Dermatitis, Atopic; Hypersensitivity | Details |
| Dectrekumab/VAK-694 | QBX-258 | Phase 2 Clinical | Novartis Pharma Ag | Asthma; Lymphedema | Details |
| JNJ-5939 | JNJ-5939; NM-26; NM26-2198; JNJ-95475939 | Phase 2 Clinical | Numab Therapeutics Ag | Dermatitis, Atopic; Inflammation | Details |
| APG-279 | APG279; APG-990/APG777 | Phase 2 Clinical | Apogee Therapeutics Inc | Dermatitis, Atopic | Details |
| CM-512 | CM512; CM-512 | Phase 2 Clinical | Keymed Biosciences Co Ltd | Asthma; Bronchiectasis; Chronic rhinosinusitis with nasal polyps (CRSwNP); Chronic Urticaria; Dermatitis, Atopic; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis | Details |
| Zumilokibart | PR004; PR-004; APG-777; APG 777; APG777 | Phase 2 Clinical | Apogee Therapeutics Inc | Asthma; Dermatitis, Atopic | Details |
| Ompekimig | PF-07264660 | Phase 2 Clinical | Pfizer Inc | Dermatitis, Atopic | Details |
| SC-CAR4BRAIN | Phase 1 Clinical | Seattle Children'S Hospital | Carcinoma; Carcinoma, Hepatocellular; Central Nervous System Neoplasms; Desmoplastic Small Round Cell Tumor; Diffuse Intrinsic Pontine Glioma; Diffuse midline glioma; Endodermal Sinus Tumor; Hepatoblastoma; Liposarcoma; Neoplasms, Germ Cell and Embryonal; Neuroblastoma; Neurofibrosarcoma; Osteosarcoma; Retinoblastoma; Rhabdoid Tumor; Rhabdomyosarcoma; Sarcoma; Sarcoma, Clear Cell; Sarcoma, Ewing; Sarcoma, Synovial; Solid tumours; Wilms Tumor | Details | |
| Dupixent biosimilar (Chong Kun Dang Pharmaceutical) | CKD-706 | Phase 1 Clinical | Chong Kun Dang Pharmaceutical Corp | Dermatitis, Atopic | Details |
| Dupilumab biosimilar (China Resources Biopharma) | Phase 1 Clinical | China Resources Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| APG273 | APG273; APG-273 | Phase 1 Clinical | Apogee Therapeutics Inc | Asthma; Pulmonary Disease, Chronic Obstructive | Details |
| Dupilumab biosimilar (Jiangsu Jingxing Pharma) | Phase 1 Clinical | Jiangsu Jingxing Pharmaceutical Technology Co Ltd | Dermatitis, Atopic | Details | |
| Dupilumab biosimilar (Chengdu Kanghong) | KH-816; KH816 | Phase 1 Clinical | Chengdu Kanghong Biotechnologies Co Ltd | Dermatitis, Atopic | Details |
| WIN-027 | QX027N; QX-027-N; WIN027; WIN-027 | Phase 1 Clinical | Qyuns Therapeutics Co Ltd | Asthma; Dermatitis, Atopic | Details |
| Dupilumab biosimilar (Jushi Biopharma) | Phase 1 Clinical | Jushi Biopharmaceutical Co Ltd | Dermatitis, Atopic | Details | |
| ATTO-3712 | ATTO-3712 | Phase 1 Clinical | Attovia Therapeutics Inc | Dermatitis, Atopic; Pruritus | Details |
| GB-7624 | GB-7624 | Phase 1 Clinical | Generate Biomedicines Inc | Dermatitis, Atopic | Details |
| ZL-1503 | ZL-1503 | Phase 1 Clinical | Zai Lab Ltd | Dermatitis, Atopic | Details |
| SAR-444765 | SAR444765; SAR-444765 | Phase 1 Clinical | Sanofi | Inflammation | Details |
| Dupilumab biosimilar (Bio-Thera Solutions) | BAT2406; BAT-2406 | Phase 1 Clinical | Bio-Thera Solutions Ltd | Asthma; Dermatitis, Atopic; Eosinophilic Esophagitis; Nasal Polyps; Prurigo Nodularis; Sinusitis | Details |
| SAR-443726 | SAR-443726 | Phase 1 Clinical | Sanofi | Dermatitis, Atopic | Details |
| English Name | Research Code | Highest Development Stage | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indication | Clinical Trial |
|---|---|---|---|---|---|---|---|---|---|---|
| Dupilumab | REGN-668; SAR-231893 | Approved | Regeneron Pharmaceuticals Inc, Sanofi | Dupixent, 达必妥 | United States | Dermatitis, Atopic | Regeneron Pharmaceuticals Inc | 2017-03-28 | Allergic Fungal Rhinosinusitis; Alopecia Areata; Angioedema; Aspergillosis, Allergic Bronchopulmonary; Asthma; Asthma, Aspirin-Induced; Chronic Urticaria; Colitis, Ulcerative; Conjunctivitis, Allergic; Coronavirus Disease 2019 (COVID-19); Dermatitis; Dermatitis, Atopic; Eczema; Eosinophilic Esophagitis; Eosinophilic gastroenteritis (EG); Genetic Diseases, Inborn; Hypereosinophilic Syndrome; Hypersensitivity; Hypersensitivity, Immediate; Keloid; Keratoconjunctivitis; Lichenoid Eruptions; Milk Hypersensitivity; Nasal Polyps; Nephrotic Syndrome; Neurodermatitis; Paranasal Sinus Diseases; Peanut Hypersensitivity; Pemphigoid, Bullous; Prostatic Neoplasms; Prurigo; Prurigo Nodularis; Pruritus; Pulmonary Disease, Chronic Obstructive; Respiration Disorders; Respiratory Sounds; Respiratory Tract Diseases; Rhinitis, Allergic; Scleroderma, Localized; Sinusitis; Skin Diseases; Skin Diseases, Eczematous; Sleep Apnea Syndromes; Urticaria | Details |
| Berdazimer sodium | NVN-1000-SB-206-Novan; SB-206; MAP3-NONOate - SB-206; NVN1000-SB206; SB-019; NI-MC101; SB-207; SB-208; SB-204; SB-414 | Approved | University Of North Carolina At Chapel Hill | KINSOLUSTM, Zelsuvmi, ZELSUVMI | United States | Molluscum Contagiosum | Lnhc Inc | 2024-01-05 | Acne Vulgaris; Condylomata Acuminata; Dermatitis, Atopic; Molluscum Contagiosum; Psoriasis; Tinea Pedis | Details |
| Lebrikizumab | RO 5490255; TNX 650; Anti-IL-13; TNX-650; RG-3637; RO-5490255; RO-4909832; PRO-301444; DRM-06; MILR-1444A; R-3637; DRM 06; LY 3650150; MILR1444A; MILR1444Ab; RG 3637 | Approved | Tanox Inc | EBGLYSS | EU | Dermatitis, Atopic | Almirall Sa | 2023-11-16 | Alzheimer Disease; Asthma; Chronic rhinosinusitis with nasal polyps (CRSwNP); Dermatitis; Dermatitis, Atopic; Eczema; Hodgkin Disease; Idiopathic Pulmonary Fibrosis; Nasal Polyps; Pulmonary Disease, Chronic Obstructive; Rhinitis, Allergic; Sinusitis; Skin Diseases; Skin Diseases, Genetic | Details |
| Tralokinumab | BAK-502G9; CAT-354 | Approved | Medimmune Llc | Adtralza, ADBRY | EU | Dermatitis, Atopic | Leo Pharma A/S | 2021-06-17 | Asthma; Colitis, Ulcerative; Dermatitis, Atopic; Eczema; Idiopathic Pulmonary Fibrosis | Details |